143 related articles for article (PubMed ID: 8402715)
1. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells.
Ferrini S; Cambiaggi A; Sforzini S; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
Cancer Detect Prev; 1993; 17(2):295-300. PubMed ID: 8402715
[TBL] [Abstract][Full Text] [Related]
2. Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules.
Ferrini S; Cambiaggi A; Cantoni C; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
Int J Cancer Suppl; 1992; 7():15-8. PubMed ID: 1428398
[TBL] [Abstract][Full Text] [Related]
3. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones.
Ferrini S; Prigione I; Miotti S; Ciccone E; Cantoni C; Chen Q; Colnaghi MI; Moretta L
Int J Cancer; 1991 May; 48(2):227-33. PubMed ID: 1826900
[TBL] [Abstract][Full Text] [Related]
4. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation.
Ferrini S; Cambiaggi A; Sforzini S; Marciano S; Canevari S; Mezzanzanica D; Colnaghi MI; Grossi CE; Moretta L
Int J Cancer; 1993 Dec; 55(6):931-7. PubMed ID: 8253530
[TBL] [Abstract][Full Text] [Related]
5. Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR.
van de Griend RJ; Bolhuis RL; Stoter G; Roozemond RC
J Immunol; 1987 May; 138(10):3137-44. PubMed ID: 2952709
[TBL] [Abstract][Full Text] [Related]
6. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
7. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
[TBL] [Abstract][Full Text] [Related]
8. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
[TBL] [Abstract][Full Text] [Related]
10. Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 x anti-CD16) antibodies.
Malygin AM; Somersalo K; Timonen T
Immunology; 1994 Jan; 81(1):92-5. PubMed ID: 7510664
[TBL] [Abstract][Full Text] [Related]
11. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with bispecific antibodies.
Thielemans KM
Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
[TBL] [Abstract][Full Text] [Related]
13. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
[TBL] [Abstract][Full Text] [Related]
14. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
[TBL] [Abstract][Full Text] [Related]
15. Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy.
Blum S; Milesi R; Tratkiewicz J; Olive D; Gallati H; Cerottini JC; von Fliedner V
Ther Immunol; 1994 Jun; 1(3):143-52. PubMed ID: 7584490
[TBL] [Abstract][Full Text] [Related]
16. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
17. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
[TBL] [Abstract][Full Text] [Related]
18. Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3.
Blank-Voorthuis CJ; Braakman E; Ronteltap CP; Tilly BC; Sturm E; Warnaar SO; Bolhuis RL
J Immunol; 1993 Sep; 151(6):2904-14. PubMed ID: 8376761
[TBL] [Abstract][Full Text] [Related]
19. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
[TBL] [Abstract][Full Text] [Related]
20. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.
Qian JH; Titus JA; Andrew SM; Mezzanzanica D; Garrido MA; Wunderlich JR; Segal DM
J Immunol; 1991 May; 146(9):3250-6. PubMed ID: 1826709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]